Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions

Uterine carcinoma (UC) is the most common gynecologic malignancy in the United States. <i>TP53</i> mutant UCs cause a disproportionate number of deaths due to limited therapies for these tumors and the lack of mechanistic understanding of their fundamental vulnerabilities. Here we sought...

Full description

Bibliographic Details
Main Authors: Katherine N. Lynch, Joyce F. Liu, Nikolas Kesten, Kin-Hoe Chow, Aniket Shetty, Ruiyang He, Mosammat Faria Afreen, Liping Yuan, Ursula A. Matulonis, Whitfield B. Growdon, Michael G. Muto, Neil S. Horowitz, Colleen M. Feltmate, Michael J. Worley, Ross S. Berkowitz, Christopher P. Crum, Bo R. Rueda, Sarah J. Hill
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
Aurora kinase
LKB1
uterine cancer
p53
G2/M cell cycle checkpoint
Online Access:https://www.mdpi.com/2072-6694/13/9/2195

Internet

https://www.mdpi.com/2072-6694/13/9/2195

Similar Items